Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11015580 | Biochemical and Biophysical Research Communications | 2018 | 6 Pages |
Abstract
An accurate assessment of HER2 status in patients with colorectal cancer is very important, because only the patients overexpressing HER2 can benefit most from the anti-HER2 targeted therapy. In this study, we investigated the feasibility of detecting HER2 expression in colon cancer by SPECT imaging using 125I-Herceptin, which showed high labeling rate, good in vitro stability and high binding specificity for HER2. HER2-positive mouse colon adenocarcinoma cell line (MC 38) was chosen as the colon caner cell model, and used for the establishment of colon cancer-bearing nude mice model. SPECT/CT imaging suggested that the tumors can be visualized at 12â¯h after the injection of 125I-Herceptin, and the uptake of tracer in tumors reached the peak at 24â¯h after injection, and can be attenuated significantly by pretreatment with an excess of nonlabeled Herceptin. These results indicates that 125I-Herceptin can be considered as an effective SPECT probe for the non-invasive detection of HER2 expression in colon cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Guixia Pan, Danni Li, Xiao Li, Ye Peng, Tao Wang, Changjing Zuo,